secwatch.observer — SEC 8-K summary
======================================

Issuer:     Opus Genetics, Inc. (IRD)
CIK:        0001228627
Form:       8-K
Filed at:   2023-11-13T23:59:59+00:00
Accession:  0001140361-23-052736
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ocuphire Q3 net income $5.6M ($0.26 EPS); revenue $11.9M; FDA agrees Phase 3 endpoint for APX3330; RYZUMVI approved
--------------------------------------------------------------------------------

- Q3 net income $5.6M ($0.26 basic EPS) vs $4.5M loss ($0.22 loss) a year ago; revenue $11.9M from $0.
- Cash $42.4M; management believes sufficient into 2025.
- Successful End-of-Phase 2 FDA meeting for APX3330; Phase 3 endpoint agreed (3-step worsening on DRSS).
- RYZUMVI (phentolamine) FDA approved for mydriasis reversal; Ocuphire received $10M milestone from Viatris.
- VEGA-2 Phase 3 presbyopia trial met primary endpoint; Viatris to continue Phase 3 development in 1H 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1228627/000114036123052736/0001140361-23-052736-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1228627/000114036123052736/ef20014551_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-052736

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer